Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

open additional study centers for the ongoing pharmacokinetic study, to undertake a clinical trial for L-DOS47 in Poland, and to undertake a European Phase III trial of Topical Interferon Alpha-2b. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "future", "next", "intends", "2010", "2011", "expects", "projects", "plan", "anticipates", "scheduled", or any other variations thereon, or that events or conditions "will", "may" or "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results. Although Helix believes that the expectations reflected in such forward-looking statements and information are reasonable, such statements and information involve risks and uncertainties, and undue reliance should not be placed on such statements and information. Certain material factors or assumptions are applied in making forward-looking statements and providing forward-looking information, and actual results may differ materially from those expressed or implied in such statements and information. Important factors that could cause actual results to differ materially from these forward-looking statements and information include, without limitation, the Company's continuing need for additional capital, which may not be available in a timely manner or at all and which if not obtained will have a material adverse impact on the Company and its ability to continue, or if not obtained in a timely manner, may result in the Company's having to discontinue or delay one or more of its product development programs or other initiatives; the ongoing impact of the global economic downturn and credit crisis which have and continue to negatively affect the availability and terms of debt and equity financings; uncertainty whether an IND will be compiled or filed for Topical Interferon Alpha-2b or L-DOS47 as currently planned or at all, or if filed, whether the Company will be permi
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015   IBA Molecular, a global leader ... that it has signed a definitive agreement to sell ... NA), to Illinois Health and Science (IHS). Under IHS ownership, ... company headquartered in Dulles, Virginia , ... new product and footprint synergies. IBA Molecular is jointly ...
(Date:4/17/2015)... April 17, 2015 TWi Pharmaceuticals, Inc. ("TWi", ... Pharmaceuticals USA , has obtained state ... States.  It has been in close contact with the ... to have its own label specialty generic products sold ... U.S. pharma market. According to IMS Health, ...
(Date:4/16/2015)... 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... 2015 on Wednesday, May 6, 2015, following the close of ... investor conference call and live webcast on the same day ... and discuss the financial results.  To access ... under the "Investors" link.  Please log onto the webcast prior ...
Breaking Medicine Technology:Health Care System to Acquire IBA Molecular North America 2Health Care System to Acquire IBA Molecular North America 3Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... Va., Nov. 9, 2010 MicroAire Surgical Instruments LLC ... an agreement to settle a suit accusing Arthrex of ... the patented technology that MicroAire owns for minimally invasive ... K. Moon of the U.S. District Court for the ...
... MYSTIC, Conn., Nov. 9, 2010 Amarin Corporation plc (Nasdaq: ... Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 ... the third quarter, including a progress update of the Company,s ... trials of its lead product candidate AMR101 for treating elevated ...
Cached Medicine Technology:MicroAire and Arthrex Agree to Amicable Settlement on ECTR Patent 2Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010 2
(Date:4/17/2015)... John Evans, a Gardant affordable assisted ... from 2 p.m. to 3 p.m. on April 24. ... Ct. in Pekin, Illinois, serves older adults of all ... to maintain their independence. , Becky Baker will entertain ... be served during the luau. , For more information, ...
(Date:4/17/2015)... 17, 2015 ERGO-Pedic Products, LLC, which ... two new products to help a broader range of ... relief are the second most common visitors to doctors. ... designed specifically to help relieve sitting pain. Then, only ... thousands of happy customers later, we began getting questions ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Alcohol and ... Dependence (NCADD) notes that drinking and driving has been ... At the same time, the link between alcohol and ... domestic abuse and violence and sexual assault, and their ... to the NCADD, 5.3 million adults in America were ...
(Date:4/17/2015)... “We have seen healing, a lot of healing, ... said Chaplain Shawn Kafader of Friendship Village. “People have ... anything to contribute have created beautiful pieces of art.” For ... therapy program that was launched to benefit residents of the ... of the Art Institute in Chicago, worked as an intern ...
(Date:4/17/2015)... D.C. (PRWEB) April 17, 2015 In ... issued the following statement: “On Wednesday April 15th, the ... and adopted a resolution recognizing the Armenian Genocide, “paying ... memory of the one-and-a-half million innocent Armenian victims who ... Christians (IDC) extols the EU for this timely and ...
Breaking Medicine News(10 mins):Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... the most serious adverse effects, yet there are also many ... first report from the National Register of Adverse Effects from ... "The Register gives us a better overview of the ... and who experiences them. Then we can make an assessment ...
... Women with ovarian cancer could be helped by a new ... a conference will hear this week. Researchers at ... doctors to personalise treatment programmes so that patients receive the ... from Ireland to identify six subgroups of the disease, each ...
... 30 (HealthDay News) -- Although stress can exacerbate multiple sclerosis ... the disease in the first place, new research indicates. ... ranging in age from 24 to 55, from the Nurses ... about their levels of stress both at home and at ...
... BROOK, Ill. Functional magnetic resonance imaging (fMRI) may ... to researchers at Columbia University in New York City, ... autistic children. Results of their study appear online and ... Autism is a spectrum disorder characterized by repetitive behaviors ...
... antibiotic resistance called New Delhi metallo--lactamase-1 (NDM-1), endemic in ... in two people in the Toronto area, one of ... in CMAJ ( Canadian Medical Association Journal ... outlines challenges and approaches to managing and identifying this ...
... News) -- ,In the wake of tennis star Serena Williams, ... College of Foot and Ankle Surgeons has a reminder: it,s ... caused when blood clots travel to the lungs, often from ... Women are at higher risk than men, as are overweight ...
Cached Medicine News:Health News:Cosmetics can cause serious adverse effects 2Health News:Targeted testing offers treatment hope for ovarian cancer patients 2Health News:New research may lead to improved diagnosis of autism 2Health News:New Delhi metallo-beta-lactamase-1 enzyme acquired in Canada 2Health News:Take Steps to Prevent Pulmonary Embolisms 2
... Iodine Prep Solution is appropriate for ... wet soak or spray); disinfecting of ... treatment of lacerations and abrasions. It ... agent in hospital and office procedures, ...
Pre-Saturated Sponge Sticks...
... trays to dry trays to specialty vaginal ... Cardinal Health offers the widest offering in ... components that are proven to be safe ... of surgical site infections. Cardinal Health Scrub ...
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
Medicine Products: